Published in Hepatology on October 01, 2010
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One (2011) 1.39
Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One (2011) 1.38
Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology (2011) 1.30
HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology (2012) 1.30
Genetics of IL28B and HCV--response to infection and treatment. Nat Rev Gastroenterol Hepatol (2012) 1.20
Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med (2013) 1.16
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica (2011) 1.00
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
Immunologic, metabolic and genetic factors in hepatitis C virus infection. World J Gastroenterol (2014) 0.96
The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon (2014) 0.90
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med (2014) 0.89
Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol (2012) 0.88
The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C. Hepat Mon (2011) 0.88
Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol (2015) 0.88
Dynamics of HCV RNA levels during acute hepatitis C virus infection. J Med Virol (2014) 0.87
Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PLoS One (2015) 0.87
IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2011) 0.86
Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection-the InC3 Study. J Infect Dis (2015) 0.85
The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Transl Med (2012) 0.85
Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS (2012) 0.84
Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. J Prev Med Hyg (2013) 0.83
Impaired hepatitis C virus (HCV)-specific interferon-γ responses in individuals with HIV who acquire HCV infection: correlation with CD4(+) T-cell counts. J Infect Dis (2012) 0.83
Role of interleukin-28B genetic polymorphisms in Korean patients with hepatitis C virus infection. Gut Liver (2013) 0.83
The natural killer cell response to HCV infection. Immune Netw (2013) 0.82
Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. J Viral Hepat (2015) 0.82
Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. J Clin Virol (2014) 0.82
Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus. PLoS Curr (2011) 0.82
IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am (2012) 0.81
Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis. Exp Ther Med (2011) 0.81
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection. PLoS One (2013) 0.81
Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study. PLoS One (2014) 0.80
Characterization of the Interleukin-28B Gene rs12979860 C/T Polymorphism in Turkish Chronic Hepatitis C Patients and Healthy Individuals. Balkan Med J (2015) 0.79
Interferon induced protein 10 remains a useful biomarker of treatment failure in patients stratified for the interleukin-28B rs12979860 haplotype. Hepatology (2011) 0.79
Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases (2015) 0.79
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment. J Gastroenterol Hepatol (2013) 0.78
Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals. Int J Mol Sci (2015) 0.77
Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother (2011) 0.76
Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat (2015) 0.75
Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment. Gastroenterology Res (2014) 0.75
Innate immunity: a new chapter for hepatitis C. Ann Gastroenterol (2012) 0.75
Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. Open Forum Infect Dis (2016) 0.75
Hepatobiliary quiz-3 (2012). J Clin Exp Hepatol (2012) 0.75
Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 5.10
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology (2006) 2.96
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol (2005) 2.63
Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis (2007) 2.16
Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology (2006) 2.11
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology (2004) 1.51
Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci (2009) 1.25
Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15
Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect (2006) 1.04
New insights into the immunopathogenesis of chronic hepatitis C. Antiviral Res (2009) 0.97
Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection. J Viral Hepat (2010) 0.87
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol (2012) 6.05
Relation between HIV viral load and infectiousness: a model-based analysis. Lancet (2008) 5.74
Cancer incidence before and after kidney transplantation. JAMA (2006) 4.77
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet (2006) 4.45
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Mass Drug Administration for Scabies Control in a Population with Endemic Disease. N Engl J Med (2015) 4.06
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual men. AIDS (2009) 3.61
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res (2009) 3.39
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J (2006) 2.93
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia. Lancet (2005) 2.83
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol (2006) 2.70
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology (2008) 2.70
Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (2003) 2.69
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology (2009) 2.66
Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS (2010) 2.65
Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol (2003) 2.65
Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum (2007) 2.56
Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis (2012) 2.51
Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology (2002) 2.51
A high-density screen for linkage in multiple sclerosis. Am J Hum Genet (2005) 2.50
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis (2009) 2.43
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis (2010) 2.41
Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol (2008) 2.39
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
"Serosorting" in casual anal sex of HIV-negative gay men is noteworthy and is increasing in Sydney, Australia. AIDS (2006) 2.26
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 2.24
Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis (2009) 2.24
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med (2015) 2.14
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog (2011) 2.13
Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol (2003) 2.13
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology (2009) 2.10
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (2011) 2.05
Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders. Hepatology (2008) 2.03
Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2009) 2.02
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS (2002) 1.98
Cockroaches keep predators guessing by using preferred escape trajectories. Curr Biol (2008) 1.95
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology (2009) 1.91
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology (2011) 1.89
Direct activation of cytosolic Ca2+ signaling and enzyme secretion by cholecystokinin in human pancreatic acinar cells. Gastroenterology (2008) 1.89
Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol (2011) 1.88
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis (2007) 1.87
Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction (2006) 1.87
Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS (2004) 1.85
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS (2010) 1.81
Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.79
The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol (2003) 1.78
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Surveillance for newly acquired hepatitis C in Australia. J Gastroenterol Hepatol (2004) 1.77
To exercise or not to exercise in chronic fatigue syndrome? No longer a question. Med J Aust (2004) 1.77
Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology (2010) 1.77